Looking at the raw quarterly tape first: revenue progression is $145.8M → $166.0M → $180.9M → $200.7M → $255.7M → $314.6M → $334.2M → $367.2M. That's not "decelerating" in absolute terms — Q4'25 grew 83% YoY and 9.9% sequentially. The Q1'25 jump from $200.7M to $255.7M (27% sequential) is the AKESO/Ambry consolidation tell, which is why YoY comps look so heroic. Strip out the inorganic step-function and the underlying organic rate is more like 30-40%, not 83%. The Revenue Confidence model flagging "decelerating" is technically right on sequential growth rates (27% → 23% → 6% → 9.9%), and that matters for anyone underwriting an 83% trajectory continuing.

On margins, the loss profile is genuinely improving — 2024 op loss of -$691M on $693M revenue (-100%) collapsed to -$239M on $1.27B (-19%) in 2025. That's real operating leverage, but the Q4'25 net margin of -14.8% versus Q3'25 at -23.9% is noisy; quarterly NI bounces between -$13M and -$80M with no clean trend. Gross margin at 69.6% is the strongest data point in the file — that's software-like and supports the platform thesis. But OCF at -$218M against $605M cash means roughly 2.5-3 years of runway at current burn before they need capital, and the balance sheet shows no reported debt figure, which is suspicious given they did a convertible offering. I'd want to verify that before sizing anything.

The insider activity is unambiguous: I count ~360k+ shares sold across late Feb and late March 2026, against awards of ~276k. Net selling, and the March 26 cluster of six separate sales on the same day suggests a coordinated 10b5-1 cadence by multiple insiders — not a single executive's liquidity event. At $52 with the stock down 50% from $104, insiders aren't buying the dip. That's a real signal, not noise.

Where I push back on the prior models: the synthesis verdict of "High Conviction Required" is fine as a label but the fair-value anchor of "$35-40 (5x sales) or proof of 20%+ EBITDA margins" is the honest part and gets buried. Market Forces calling for a 50%+ reset is too aggressive given the gross margin profile and growth — Veeva trades at 13x sales profitably, Illumina trades at 4x sales as a no-growth incumbent; Tempus at 7.2x with 30-40% organic growth and improving operating leverage probably belongs at 5-6x sales, i.e. $35-42. Pre-Flight's read that the market has already repriced from blue-sky to "prove it" is correct, but "priced for strong execution" understates how much the convertible/dilution math degrades the equity story if they need to raise at these levels. The contrarian argument the models underweight: this is Eric Lefkofsky, and Groupon was a cautionary tale about a founder who optimized for growth narrative over unit economics until the music stopped. The pharma Insights segment lumpiness (Q3 weakness, Q4 rebound) hints at deal-timing dependency that won't show up until a bad quarter prints.

What's thin in the data: no debt figure, no equity figure, no FCF CAGR, no earnings CAGR — all blank. The TTM-derived ratios (ROE -60%, ROIC -10%) are uninformative for a pre-profit name and the anomaly flags are right to demote them. The ev_to_revenue of 8.26 vs ps of 8.09 is internally consistent and the only multiple worth anchoring on.

I dissent partially with the synthesis. "High Conviction Required" at $52 implies it's roughly fair if you believe; I think it's modestly expensive even if you believe, because the organic growth rate is closer to 35% than 83%, gross margin gains have largely played out (you don't get from 70% to 85%), and insiders are telling you with their feet. Fair value on a 5-6x forward sales multiple ($1.6-1.7B '26 revenue) lands at $42-50/share — basically here, with downside skew. I'd want $38-42 for a starter and would not chase.